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Abstract Lung cancer is the leading cause of cancer-related
deaths worldwide. The case-fatality rate of lung cancer re-
mains exceptionally high at 95% despite numerous medical
advancements in therapeutic strategies in the last decades.
However, patients diagnosed at Stage I are commonly curable
and have a 5-year survival rate of 50–80%. Unfortunately,
delayed diagnosis of lung cancer has been unavoidable and
is an important factor in the overall outcome of treatment.
Accordingly, screening of high-risk individuals is likely to
have hugely beneficial outcomes for patient survival.
Current screening approaches include low-dose computed to-
mography and chest X-ray. Recently, alternative approaches
for lung cancer screening have been developed including anal-
ysis of biomarkers, including DNA, RNA, proteins, and anti-
bodies in blood, sputum, bronchoalveolar lavage (BAL), and
breath. Biomarker analysis would also provide critical infor-
mation regarding tumor growth pattern, cells of origin of
tumor, subtype of lung cancer, and/or drugmetabolism as well
as monitor patient prognosis. Novel non-invasive lung cancer
diagnostic strategies could improve and complement the suc-
cess of CT-scan and chest X-ray.
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Introduction
Lung cancer is a highly prevalent disease and is the foremost
cause of cancer-related deaths worldwide, i.e., 25% of cancer-
related deaths [1]. In 2012, it accounted for approximately 1.6
million deaths, which means more deaths than three well-
known cancer types put together such as, breast, prostate,
and colorectal cancers. Themortality rate of lung cancer close-
ly parallels the incidence pattern resulting in an extremely
high-case fatality rate of 95%. The persistently low patient
survival is reflected in a 5-year survival rate of 15–17% [1,
2]. Epidemiological observations performed across varied de-
mographic cohorts in India point towards a similar pattern of
incidence and mortality, underlining the significant burden of
lung cancer towards mortality and morbidity in India [3, 4].
The GLOBOCAN 2012 report estimated lung cancer inci-
dence in India to be 70,275 (6.9%) across all ages and both
sexes, and the estimation was 63,759 (9.3%), making it the
third most common cause of cancer-related mortality in India
after breast and cervical cancers (Fig. 1) [5]. However, it is
speculated that the illustrated incidence and mortality patterns
represent an underestimation of the overall lung cancer burden
due to the quality of data acquired from regional hospital-
based registries. According to the report of the National
Cancer Registry Programme, there is significant (rise in) lung
cancer incidence in Delhi, Chennai, and Bengaluru in both
sexes. The incidence and pattern of lung cancer differ as per
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